FILING ANALYSIS · THURSDAY, NOVEMBER 12
Monopar Therapeutics MNPR — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $6.2 million and increased R&D expenses, but has sufficient cash to support operations through at least March 31, 2028, and is on track to complete the NDA submission for ALXN1840 within the next several weeks. There are no quantified surprises in the filing that would significantly impact the stock price.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →